InSilico Medicine (HKG:3696) nominated ISM1354, a next-generation small-molecule GIPR antagonist, as a preclinical candidate for potential treatment of obesity and related disorders, including type 2 diabetes, according to a Wednesday Hong Kong bourse filing.
The candidate was developed using InSilico Medicine's proprietary generative AI platform.
The company said ISM1354 retains favorable drug-like properties while offering improvements across pharmacokinetic and safety profiles.
Shares of the firm were up more than 8% in Wednesday afternoon trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments